DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 98% dehydrated alcohol; A04AD10; ACETYLCYSTEINE; ANTOX; ANTOX (vers) 1.2; ANTOX (vers.)1.2; ASCORBIC ACID; Acetate; Acetyl-L-carnitine; Acetyl-L-carnitine 1000mg 2X per day for 3 months; Acetylcysteine; Alanine; Alcohol; Alpha 1-Antitrypsin; Alpha 1-antitrypsin; Amino acids; Amlodipine; Amlodipine (drug); Analgesics; Antioxidant plus Pregabalin; Antioxidants; Antox version 1.2; Ascorbic acid; Autologous mesenchymal stromal cell; Behavioral: smoking and alcohol assumption; Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala); Bupivacaine; Bupivicaine alone; CREON; Calcium; Calcium, Dietary; Carbon; Carbon monoxide; Carnitine; Cholecalciferol; Creon; Creon 10000; Creon 25000; Creon36™; DRONABINOL; Device: Mayo Interactive Breath Hold Monitor; Diagnostic Test: Hemoglobin A1c; Diagnostic Test: Mixed Meal Tolerance Test; Diagnostic Test: Other exploratory blood biomarkers; Diagnostic Test: genetic sequencing; Diazepam; Dronabinol; ERCP with Bupivacaine infusion; EUR-1008 (APT-1008) High Dose; EUR-1008 (APT-1008) Low Dose; EUR-1066-A; EUR-1066-B; EUS procedure with drug injection; Ensure Surgical; Esomeprazole; Etanercept; FLUIMUCIL*20CPR EFF 600MG; Fluimucil; Gabapentin; Gabapentin prescriptions; Gold; Helopanflat Mono®; Hemoglobin; Human Secretin; Human secretin; Hydroxychloroquine; Indomethacin; Intra Plexus Triamcinolone and Bupivicaine Injection; Kreon 25000; L-Carnitine; LANREOTIDE ACETATE; LIPASE; Lannacher; Lanreotide; Liprotamase; Lyrica; Lyrica®; MAGNESIUM ASPARTATE HYDROCHLORIDE; METHIONINE; MONITOR; MS1819; MS1819-SD; Magnesiocard 2.5mmol; Magnesium; Magnesium aspartate; Methionine; Mezym F; Midazolam; Multienzymes (lipase, protease etc.); NI-03; Namisol; Nexium (esomeprazole magnesium); OXYCODONE; OXYCODONE HYDROCHLORIDE; Omeprazole; Other: Carbon monoxide-bubbled mediums; Other: EUS procedure; Other: Laboratory Biomarker Analysis; Other: Low-intensity exercise therapy; Other: No enzyme therapy; Other: Nutrition counseling; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Oxycodone; Oxycodone Depot ”Sandoz”, depot tablets; Oxycodonhydrochlorid ”Lannacher”, depot tablets; Oxynorm; PFD; PL 00512/0150; Pancreatic enzymes; Pancreatin; Pancrelipase; Pancrelipase Delayed Release Capsule; Pancrelipase delayed release capsule; Pancrelipase/Pancreas Powder; Panzytrat; Panzytrat 25.000; Panzytrat 25.000 FIP-E units of Lipase; Pentoxifylline; Perflubutane; Pioglitazone; Pregabalin; Procedure: Celiac Block with triamcinolone and bupivicaine; Procedure: No Celiac Block; Procedure: endoscopic drainage of the main pancreatic duct; Procedure: extracorporeal shock wave lithotripsy; Prolastin; Prolastin-C; Proton pump inhibitor (PPI); REGN475/SAR164877; RG1068 (Synthetic Human Secretin); RVG 13760; Radiation: UV-filtered light.; Radiation: UVB; Recombinant Microbial Lipase SLV339; Recombinant microbial lipase; Reparixin; S-Ketamin; S-ketamin; SA; SA-001; SELENIUM; SLV339; Secretin; Selenium; Simvastatin; Somatuline; Somatuline Autogel 90 mg; Soy bread; Synthetic human secretin; TOCOPHEROL; Tanezumab; Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol; Tetrahydrocannabinol; Thalidomide; Tocopherol; Triamcinolone; Tyr; VIOKASE 16; Viokase 16; Viokase 16 (pancrelipase) + Nexium; Viokase® 16; Vitamin D; Vitamin D 100ug; Vitamin D 10ug; Yarrowia lipolytica lipase; ZENTASE; Zenpep

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004004-12-BG (EUCTR)	28/02/2008	05/02/2008	A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY	A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY	Pancreatic enzyme replacement therapy is the cornerstone of nutritional management of pancreatic exocrine insufficiency (PEI) due to e.g. cystic fibrosis, chronic pancreatitis, partial or complete pancreatectomy or gastrectomy. Without pancreatic enzyme replacement the patients suffer from severe symptoms of maldigestion as manifested by steatorrhea, abdominal pain, body weight loss etc. MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis MedDRA version: 9.1;Classification code 10033596;Term: Pancreatectomy	Trade Name: Creon 10000 Product Name: Pancrelipase Delayed Release Capsule Other descriptive name: Pancrelipase /Pancreas Powder Trade Name: Creon 25000 Product Name: Pancrelipase Delayed Release Capsule Other descriptive name: Pancrelipase /Pancreas Powder	Solvay Pharmaceuticals GmbH	NULL	Not Recruiting			Female: yes Male: yes	52		Bulgaria
2	NCT00414908 (ClinicalTrials.gov)	October 2007	21/12/2006	A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy	A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy	Chronic Pancreatitis;Pancreatectomy;Pancreatic Exocrine Insufficiency	Drug: Pancrelipase delayed release capsule;Drug: Placebo Comparator	Solvay Pharmaceuticals	NULL	Completed	18 Years	N/A	All	52	Phase 3	United States;Bulgaria;Poland;Puerto Rico;Russian Federation;Serbia;South Africa;Ukraine;Former Serbia and Montenegro

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2007-004004-12-BG
(EUCTR)

28/02/2008

05/02/2008

A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY

Pancreatic enzyme replacement therapy is the cornerstone of nutritional management of pancreatic exocrine insufficiency (PEI) due to e.g. cystic fibrosis, chronic pancreatitis, partial or complete pancreatectomy or gastrectomy. Without pancreatic enzyme replacement the patients suffer from severe symptoms of maldigestion as manifested by steatorrhea, abdominal pain, body weight loss etc.
MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
MedDRA version: 9.1;Classification code 10033596;Term: Pancreatectomy

Trade Name: Creon 10000
Product Name: Pancrelipase Delayed Release Capsule
Other descriptive name: Pancrelipase /Pancreas Powder
Trade Name: Creon 25000
Product Name: Pancrelipase Delayed Release Capsule
Other descriptive name: Pancrelipase /Pancreas Powder

Solvay Pharmaceuticals GmbH

NULL

Not Recruiting

Female: yes
Male: yes

Bulgaria

NCT00414908
(ClinicalTrials.gov)

October 2007

21/12/2006

A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

Chronic Pancreatitis;Pancreatectomy;Pancreatic Exocrine Insufficiency

Drug: Pancrelipase delayed release capsule;Drug: Placebo Comparator

Solvay Pharmaceuticals

NULL

Completed

18 Years

N/A

All

Phase 3

United States;Bulgaria;Poland;Puerto Rico;Russian Federation;Serbia;South Africa;Ukraine;Former Serbia and Montenegro